新华社北京11月21日电 题：国际医药创新公园迎"新"记 新华社记者吉宁 "北京是拜耳在华发展的重要战略起点，落地创新公园正是我们携手本土创新力量、共建医药研发新生 态的关键环节。"近日，拜耳・亦庄开放创新中心在位于北京经济技术开发区的国际医药创新公园正式 启用，拜耳全球生命科学共创平台、首批入孵企业同步落地，拜耳集团处方药事业部全球执行副总裁兼 中国区总裁、拜耳中国区总裁周晓兰的表态，道出了众多入驻企业的心声。 更引人注目的是，依托国家人工智能应用中试基地（医疗领域）的落地，园区正加快培育AI医疗健康 产业集群，建设超级算力底座、数据标注基地、医疗健康及药品行业可信数据空间等关键基础设施，瞄 准AI+医药制造、精准诊疗两大方向，打造产业创新新优势。 "我们正在构建'产业链、创新链、人才链、生态链'体系。"北京经济技术开发区工委书记孔磊表示，国 际医药创新公园将聚焦全球顶尖生物医药企业总部及创新中心落地服务，同步打造覆盖创新产品研发、 中试到规模化生产的全周期一体化空间，为企业发展提供全链条支撑。 伴随着一次次的迎"新"，国际医药创新公园涌动着建设热潮与创新活力。接待大厅内，前来考察洽谈的 客商络绎不绝，对园 ...

近年来中国在生物医药领域的迅速发展，吸引着诸多外企的眼光和持续投资。 陈海波说："近年来中国实现了从仿制药向首创小分子、肽类和生物制剂的战略转变。一些领先的 CDMO（合同研发生产组织）、制药公司以及新兴的生物科技领域现已获得全球认可。中国吸引了数十 亿美元的生物科技风险投资，许多公司都已成功在香港交易所、科创板或纳斯达克融资。"他进一步表 示："与国际标准加强对接以及高技能科学家从海外归国等，都进一步加速了这场转型。" 再加上"健康中国2030"的规划纲要，陈海波称，嘉法狮看到了在中国市场巨大的合作潜力。据他介绍， 嘉法狮不断通过对本土人才、法规认知与配方支持的持续投入，深化与中国合作伙伴及中国药科大学、 沈阳药科大学和上海应用技术大学等中国高校的合作。 对于未来挑战，陈海波坦言："中国创新的速度很快，科研实力引领全球，如何跟上中国的创新潮流， 优先响应中国客户的需求，是重要的课题。"不过，他表示，作为一家法国企业，嘉法狮对中国的未来 非常乐观，"我们将继续增加投资，加强本地团队建设，并创造新的就业机会。我们对中国的信心坚定 不移。这是我们长期且坚定的承诺。" 据蒲爱德介绍，目前嘉法狮集团在全球拥有四大技术 ...

Core Insights - The Zhongguancun Life Science Park has transformed into a vital axis for Beijing's international technology innovation center, evolving from rural areas into a hub for life sciences and biotechnology [1][3] - The park is home to over 600 innovative pharmaceutical companies, creating a vibrant ecosystem that includes leading enterprises, innovative SMEs, supportive policies, and capital [1][2] Group 1: Innovation Ecosystem - The park features a comprehensive innovation chain that encompasses basic research, technology development, clinical validation, and production [2][3] - Key institutions such as the National Protein Science Center and various top-tier research institutes are located within the park, facilitating significant advancements in life sciences [2][3] - The park has produced notable innovations, including China's first billion-dollar drug and several cutting-edge gene editing tools recognized internationally [3][4] Group 2: Entrepreneurial Environment - The park has become a "paradise for scientists" where many researchers have founded their own companies, with 112 enterprises established by scientists [5][6] - Early support for scientific entrepreneurship is a unique attraction of the park, providing essential resources and funding for startups [6][7] - The park's strong industry cluster effect allows scientists to easily find partners and resources, significantly lowering the barriers to entrepreneurship [7][8] Group 3: Financial Support and Investment - The Beijing government has established a 20 billion yuan investment fund to support the pharmaceutical and health industry, ensuring financial backing for innovation [7][8] - The park's management has created a multi-layered investment fund matrix, collaborating with over 50 market-oriented investment funds to empower original innovations [8][9] Group 4: Future Development - The park aims to maintain its leading position in emerging fields such as cell and gene therapy, with ongoing projects and clinical trials [3][9] - The construction of third-party service platforms and technology centers is crucial for accelerating innovation and enhancing industry competitiveness [9][10] - The park is focused on expanding its global influence in the biopharmaceutical sector, with a commitment to fostering original discoveries that benefit the world [12]

礼来集团副总裁兼礼来中国总经理德赫兰表示，近年来，政策环境持续优化，生物医药产业快速发展， 中国已成为全球创新的重要策源地。礼来今年在华落地两个创新孵化器项目，将充分发挥平台效能，赋 能高潜科学创业者及其初创公司，加速研发改善人类生活质量的药物。 近年来，礼来持续在华深耕并率先与本土企业建立创新合作关系。伴随中国创新生态迭代提速，礼来先 后于2008年成立礼来亚洲风险投资风险基金，2018年落地中国创新合作中心，2022年启用张江催化器， 2024年成立礼来医学创新中心，2025年又在北京、上海双城落子创新孵化器，目前已经形成覆盖"靶点 发现—临床开发—商业化"全周期的外部创新矩阵。 （文章来源：新华财经） 新华财经上海11月9日电（记者杜康）8日，在"2025礼来中国科学日"论坛上，礼来宣布其开放创新平台 上海创新孵化器（Lilly Gateway Labs, LGL）正式投入运营，并与首家入驻企业——分子之心完成签 约。此外，会上，礼来宣布与3家本土企业——圣因生物、英矽智能、苏州阿尔脉生物科技有限公司达 成战略合作，合力按下突破性疗法上市"加速键"。 此次揭幕的礼来上海创新孵化器是继北京之后，礼来在华成 ...

Group 1 - The event emphasized the importance of high-level opening up and deepening economic and trade cooperation to expand new space and inject new momentum for high-quality development [1] - The technology and equipment exhibition showcased advanced equipment and cutting-edge technologies, with companies like General Electric, Siemens, and Honeywell participating [1] - Foreign companies expressed confidence in investing in Jiangsu, highlighting the province's strong real economy and favorable business environment [1] Group 2 - In the medical device and pharmaceutical health exhibition area, Pfizer and other companies showcased their innovative drug research and project progress [2] - Jiangsu's biopharmaceutical industry is among the largest in the country, focusing on open innovation and building an internationally competitive biopharmaceutical hub [2] - The cultural exchange exhibition area featured traditional crafts and innovative consumer products, enhancing the cultural appeal of Jiangsu [2]

Core Insights - The 2025 China Biotechnology Innovation Conference was held in Chengdu High-tech Zone, showcasing the region's strong innovation vitality and leadership in the biopharmaceutical industry, ranking fourth in the 2024 China Biopharmaceutical Industry Park Annual Competitiveness Ranking [1] Group 1: Innovation Platforms - Chengdu High-tech Zone established the "Global New Drug Discovery Center" to foster original scientific achievements and leading talents, addressing challenges in drug development by integrating resources and promoting collaboration [2] - The region has developed multiple high-level innovation platforms, including the National Precision Medicine Industry Innovation Center and Tianfu Jincheng Laboratory, to enhance source innovation and result transformation capabilities [2] Group 2: Industry Growth - Chengdu High-tech Zone has attracted over 3,000 biopharmaceutical companies and established more than 160 functional platforms, with over 300 projects introduced and a total investment exceeding 120 billion yuan [3] Group 3: Policy and Financial Support - The region has implemented comprehensive policies to support the biopharmaceutical industry, focusing on strategic construction, innovation enhancement, and ecosystem development [4] - Chengdu High-tech Zone has created a six-in-one capital support system, forming 25 funds with a total scale of 35.2 billion yuan, and introduced unique financial products like "Bio Loan" to alleviate funding bottlenecks for innovative enterprises [5] Group 4: Future Outlook - Chengdu High-tech Zone aims to continue gathering global innovation resources and deepen the integration of industry, academia, and research, contributing significantly to the development of China's biopharmaceutical industry [6]

Core Insights - Bayer's commitment to innovation in China's biopharmaceutical sector is highlighted through the successful hosting of the first "Co-Creation New Drug" competition, recognizing six biotech companies for their groundbreaking innovations in oncology, cardiovascular diseases, kidney diseases, immunology, and new technology platforms [1][4][9]. Group 1: Event Overview - The "Bayer Prescription Drug China Open Innovation Day" was held on October 28, 2025, showcasing Bayer's focus on China's innovation and new drug development capabilities [1]. - The event featured discussions among global and local management, industry experts, research institutions, investment firms, and startups, emphasizing Bayer's commitment to integrating into China's pharmaceutical innovation ecosystem [1][3]. Group 2: Strategic Focus - Bayer is concentrating on key research areas, establishing a differentiated pipeline for long-term growth in oncology, cardiovascular diseases, kidney diseases, neurology, rare diseases, and immunology [3][4]. - The company aims to leverage external collaborations to enhance its drug development process, focusing on unmet medical needs and high-value potential areas [3][4]. Group 3: Winning Companies - Six biotech companies were recognized for their innovative achievements: - **Zhihui Medicine** focuses on overcoming tumor resistance mechanisms [5][13]. - **Gaowei Medicine** utilizes advanced algorithms for drug target identification [5][14]. - **Aibelle** is developing next-generation immunotherapies for solid tumors [5][15]. - **Alpha Molecule** targets GPCRs with an AI-driven platform [5][16]. - **Shanghai Yinuo Pharmaceutical** specializes in autoimmune and chronic inflammatory diseases [5][17]. - **Yaoshu Technology** employs organ-on-chip technology for drug discovery [5][18]. - These companies will receive various rewards and support from Bayer, including entry into the Bayer Co.Lab platform and mentorship from experts [5][10]. Group 4: Bayer's Global Strategy - Bayer views China as a core strategic market for global pharmaceutical innovation and is actively exploring diverse external collaborations [4][9]. - The company has established the Bayer Co.Lab platform to support local startups and early-stage innovations, fostering a collaborative ecosystem [10].

Core Insights - AstraZeneca has officially launched its sixth global strategic R&D center in Beijing, establishing a new bridge for Sino-British pharmaceutical innovation [1] - The collaboration between AstraZeneca and Cambridge University aims to enhance connectivity, communication, and collaboration in the pharmaceutical sector, marking a new phase in Sino-British cooperation [3] - China's pharmaceutical industry is undergoing rapid transformation, driven by innovation and increasing integration into the global clinical trial landscape [4] Group 1: AstraZeneca's R&D Center and Collaborations - The new R&D center in Beijing is part of a broader strategy to strengthen the entire innovation ecosystem, enhancing capabilities from research to platform and ecosystem development [1] - The "3C" concept (Connect, Communicate, Collaborate) is central to the partnership, focusing on building trust and facilitating deeper discussions on specific research areas [3] - AstraZeneca's collaboration with Harbour BioMed in oncology and autoimmune diseases is expected to inject new momentum into drug development through a diversified cooperation model [10] Group 2: China's Pharmaceutical Innovation Landscape - The "Healthy China 2030" strategy emphasizes high-quality healthcare services and the unique advantages of pharmaceuticals, driving the rapid growth of innovative drugs [4] - By 2024, Chinese companies are expected to account for 30% of global clinical trial initiations, reflecting China's growing influence in the global clinical trial arena [4] - The increasing number of innovative drugs included in the medical insurance directory is driving the rapid growth of the original innovative drug market in China [4] Group 3: Future of Sino-British Cooperation - The partnership between AstraZeneca and local entities in Beijing represents a new model of innovation cooperation, leveraging the strengths of both sides [5] - The collaboration aims to create a comprehensive innovation ecosystem that connects early-stage research to clinical applications, enhancing the global competitiveness of Chinese pharmaceutical innovations [10][14] - The shift from simple product cooperation to a more advanced collaborative model signifies China's transition from being a "world pharmacy" to a global source of pharmaceutical innovation [14]

Core Insights - AstraZeneca officially launched its sixth global strategic R&D center in Beijing Economic-Technological Development Area, marking a significant step in establishing Beijing as a global biopharmaceutical innovation hub [1][2] - The new center aims to leverage Beijing's leading scientific ecosystem and AI advantages to accelerate the development of innovative drugs, enhancing collaboration with local clinical trial institutions, universities, and biotech companies [1][2] - AstraZeneca's investment of $2.5 billion in Beijing signifies a commitment to local innovation and collaboration, positioning the region as a key player in the global biopharmaceutical landscape [1][2] Summary by Sections AstraZeneca's New R&D Center - The new global strategic R&D center is AstraZeneca's second in China, following the establishment of the Shanghai center [1] - The center will collaborate with the Shanghai center to lead drug discovery and clinical development, facilitating the transformation of innovative results into life-changing medications [1] Collaboration with Local Entities - AstraZeneca signed a cooperation agreement with Beijing's Science and Technology Commission and other local authorities to enhance R&D innovation and local partnerships [1] - The collaboration aims to strengthen the entire chain from drug discovery to clinical development and new drug approval [1] Innovation Ecosystem Development - The partnership between AstraZeneca and Heptares Therapeutics focuses on accelerating the development of antibody drugs, particularly in oncology and autoimmune diseases [1] - The establishment of a new innovation laboratory will enhance collaborative efficiency and expedite the R&D process for next-generation antibody drugs [1] Economic Impact and Future Prospects - Beijing's BioPark is expected to create a more international business environment, attracting more global pharmaceutical companies to participate in regional development [2] - The biopharmaceutical industry in Beijing Yizhuang has over 5,000 companies, contributing nearly 90 billion yuan to the local economy, showcasing a robust development pattern [2]

Core Insights - The article highlights the transformation of the Xiamen Biopharmaceutical Port and the success story of Teva Biopharma, which has evolved from a small team to a leading company in the biopharmaceutical industry in China [1][2]. Company Overview - Teva Biopharma, established in 1996, focuses on the research, production, and sales of recombinant proteins and long-acting modified drugs, primarily in the field of immunology [2]. - The company has developed several first-class new drugs, including Pegfilgrastim, Yipeng, and Peijin, based on its innovative platform technology centered around polyethylene glycol long-acting drugs [2]. Financial Performance - From 2018 to 2024, Teva Biopharma's operating revenue increased from 448 million to 2.817 billion, while net profit rose from 16 million to 827 million [2]. - In the first half of 2025, the company reported R&D expenditures of 202 million, reflecting a year-on-year growth of 48.77% [3]. Innovation and Development - Teva Biopharma emphasizes continuous innovation, with a focus on building a core technology platform that includes PEG modification, drug production, and optimization [4]. - The company has transitioned from a small team of 7 to over 2,000 employees and successfully listed on the STAR Market in January 2020, marking a significant milestone in its development [4]. Future Outlook - The company views innovation as its greatest opportunity and recognizes the risk of losing direction in the innovation process [5]. - Teva Biopharma aims to shift from single drug development to integrated innovation through multi-path technology, addressing complex diseases and enhancing clinical efficacy and value [5].